AP-1 as a transcriptional regulator of AT2 cell reversible activation during lung injury response
AP-1 as a transcriptional regulator of AT2 cell reversible activation during lung injury response
批准号:
10535199
负责人:
ANNE LYNCH
金额:
$4.68万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-09-20 至 2025-09-19
关键词:
3-DimensionalATAC-seqAcute Lung InjuryAddressAlveolarAlveolar Cell Type IAreaBenchmarkingCOVID-19COVID-19 pandemicCause of DeathCell DeathCell Differentiation processCell ProliferationCellsChIP-seqChemical InjuryChromatinComplementComplement ActivationCountryDataDetectionDistalEpigenetic ProcessEpithelialFOSB geneGasesGenetic TranscriptionGenomic approachGoalsGrowthHeterogeneityIn SituInfectionInhalationInjuryInterventionKineticsLabelLightLobeLower Respiratory Tract InfectionLungLung AdenocarcinomaLung diseasesMalignant neoplasm of lungMapsMediatingMicroscopyModelingMolecularMusNatural regenerationNatureNuclearPersonsPhasePneumonectomyPoisonProliferatingRecoveryRespiratory Tract InfectionsRiskRoleRunningSTEM fieldSendai virusTestingThree-Dimensional ImageTimeTissuesToxinTranscription Factor AP-1Transcriptional RegulationViralVirus DiseasesXCL1 genealveolar epitheliumalveolar type II cellcombatconditional knockoutepigenetic regulationepigenomicsepithelial injurygenetic approachimaging approachinjured airwayinjury and repairinjury burdenlung injurylung lobelung regenerationmembermouse modelnovelparainfluenza viruspathogenrepairedresponse to injurysingle cell analysisspatiotemporalstem cell biologystem cell functionstem cell populationstem cellssurfactanttissue regenerationtissue repairtraining opportunitywound healing
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
Lower respiratory infections were the fourth leading cause of death worldwide for nearly twenty years, and in
2019 with the onset of the COVID-19 pandemic, respiratory infections quickly rose to the leading cause of
death in many countries killing over 5 million people worldwide thus far. Our lungs are equipped with stem cells
to help us recover from lung related injury caused by inhaling toxins and pathogens. However, like in many
COVID-19 cases, the stem cells cannot always handle the injury burden. Alveolar type II (AT2) cells are
facultative stem cells of the lung that secrete surfactant and aid with gas exchange. During injury, AT2 cells
withdraw from homeostatic quiescence to repair damage through proliferation and differentiation into alveolar
type I (AT1) cells, then revert to quiescence when the epithelium is restored. The mechanism behind AT2 cell
reversible activation is unclear. To better understand this mechanism, we modeled respiratory injury in mice
through a murine parainfluenza virus known as Sendai virus. Lineage tracing of AT2 cells and proliferation
revealed that AT2 cells not only activate to perform in situ wound repair, but also cluster and proliferate at
regions away from damage, specific to the edges of airways and vessels, as well as the most distal border of
the tissue, representing de novo growth. ATAC-sequencing was performed on AT2 cells from infected mice at
the peak of AT2 cell proliferation and in the recovery phase after returning to quiescence. AT2 cells gained
accessibility of AP-1 motifs during injury repair and subsequently lost accessibility for AP-1 motifs at recovery.
The hypothesis of this proposal is that AP-1 transcriptionally regulates AT2 cell activation to induce
both in situ and de novo repair during lung injury response. We will first identify the spatiotemporal
activation of AT2 cells during infection through lineage tracing AT2 cell proliferation and differentiation for
detection with light sheet microscopy to generate 3D images for deciphering if the proposed in situ and de
novo regions of activation are truly distinct. We will also perturb an airway stem cell population known to
contribute to in situ wound repair to study region specific changes in AT2 cell activation when airway
assistance is disrupted (Aim1). Second, we will investigate the regulatory mechanism in AT2 cell activation by
looking at the kinetics of epigenetic change over time through injury response with bulk ATAC and single-cell
mutiome-sequencing. We will also examine the role of AP-1 through AT2 cell specific conditional knockout of
FOSB to examine its impact on AT2 cell activation and repair (Aim2). This study will help characterize the
novel concept of in situ and de novo AT2 cell activation as well as the undiscovered epigenetic and
transcriptional regulation of lung regeneration.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
AP-1 as a transcriptional regulator of AT2 cell reversible activation during lung injury response
-
批准号:10843725
-
项目类别:
-
资助金额:$4.77万
-
财政年份:2022
-
负责人:ANNE LYNCH
-
依托单位:
国内基金
海外基金
登录
查看更多内容
基于ATAC-seq与DNA甲基化测序探究染色质可及性对莲两生态型地下茎适应性分化的作用机制
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:
-
依托单位:
利用ATAC-seq联合RNA-seq分析TOP2A介导的HCC肿瘤细胞迁移侵
袭的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:柳静
-
依托单位:
面向图神经网络ATAC-seq模体识别的最小间隔单细胞聚类研究
-
批准号:62302218
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:张双全
-
依托单位:
基于ATAC-seq策略挖掘穿心莲基因组中调控穿心莲内酯合成的增强子
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:黄铭坤
-
依托单位:
基于单细胞ATAC-seq技术的C4光合调控分子机制研究
-
批准号:32100438
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:涂晓雨
-
依托单位:
基于ATAC-seq技术研究交叉反应物质197调控TFEB介导的自噬抑制子宫内膜异位症侵袭的分子机制
-
批准号:82001520
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:汤小晗
-
依托单位:
靶向治疗动态调控肺癌细胞DNA可接近性的ATAC-seq分析
-
批准号:81802809
-
项目类别:青年科学基金项目
-
资助金额:21.0万元
-
批准年份:2018
-
负责人:蔡梅春
-
依托单位:
运用ATAC-seq技术分析染色质可接近性对犏牛初级精母细胞基因表达的调控作用
-
批准号:31802046
-
项目类别:青年科学基金项目
-
资助金额:27.0万元
-
批准年份:2018
-
负责人:张龚炜
-
依托单位:
基于ATAC-seq和RNA-seq研究CWIN调控采后番茄果实耐冷性作用机制
-
批准号:31801915
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2018
-
负责人:茹磊
-
依托单位:
基于ATAC-seq高精度预测染色质相互作用的新方法和基于增强现实的3D基因组数据可视化
-
批准号:31871331
-
项目类别:面上项目
-
资助金额:59.0万元
-
批准年份:2018
-
负责人:张治华
-
依托单位: